Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.76 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565212 | 0.93 | S1PR5 (0.87) | S1PR5S1PR1 | |
| SCHEMBL16301219 | 0.90 | S1PR5 (0.77) | S1PR5S1PR1KDM4EALDH1A1HPGD | |
| SCHEMBL250506 | 0.90 | S1PR5 (0.77) | S1PR5S1PR1KDM4EALDH1A1HPGD | |
| SCHEMBL9037650 | 0.90 | S1PR5 (0.77) | S1PR5S1PR1KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL892740 | 0.88 | S1PR5 (0.75) | S1PR5S1PR1KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL893221 | 0.88 | S1PR5 (0.75) | S1PR5S1PR1KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL892739 | 0.88 | S1PR5 (0.75) | S1PR5S1PR1KDM4EALDH1A1HPGD | |
| SCHEMBL3844177 | 0.87 | ALDH1A1 (0.71) | S1PR5S1PR1KDM4EALDH1A1HPGD | |
| SCHEMBL18125935 | 0.87 | ALDH1A1 (0.71) | S1PR5S1PR1KDM4EALDH1A1HPGD | |
| SCHEMBL8318203 | 0.86 | GAA (0.58) | S1PR5S1PR1SIGMAR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-7235538-B2 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| EP-1561752-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-08-10 | — | — | EP | disclosed |
| EP-1301187-B1 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK AS (DK) | 2005-07-06 | — | — | EP | disclosed |
| US-20040034014-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS BENDTZ (DK) | 2004-02-19 | — | — | US | disclosed |
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | SOD1, SOD3, SMN1; SMN2 | S1PR5 3642/4885S1PR1 2636/4885SIGMAR1 2265/4885 |
| US-20040034014-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | S1PR5 4780/4885S1PR1 4859/4885SIGMAR1 3685/4885 |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SOD1, SOD3, SMN1; SMN2 | S1PR5 3620/4885S1PR1 2615/4885SIGMAR1 2242/4885 |
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | S1PR5 4780/4885S1PR1 4859/4885SIGMAR1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.